The Therapeutic Goods Administration (TGA) has approved the world’s first Alzheimer’s blood test in Australia, which could dramatically shorten the time needed to diagnose Alzheimer’s disease. The TGA-approved Alzheimer’s test detects disease-related biomarkers from a simple blood sample, potentially replacing lengthy diagnostic pathways that often involve specialist referrals, brain scans, or spinal procedures.
The new Alzheimer’s blood biomarker test measures pTau217, a protein strongly linked to Alzheimer’s disease. Health experts believe the test could provide highly accurate results within minutes while helping patients receive an Alzheimer’s diagnosis in weeks rather than months.
What is The First Alzheimer’s Blood Test in Australia?
The newly approved Alzheimer’s blood test in Australia identifies phosphorylated tau 217 (pTau217), a biomarker which indicates abnormal changes associated with Alzheimer’s disease.
The pTau217 protein is closely linked to the buildup of amyloid plaques, sticky deposits that gradually accumulate in the brain and are considered one of the defining features of Alzheimer’s disease. Instead of relying on invasive procedures, clinicians can now use a routine blood sample to look for these biological changes.
Clinical research has shown the Alzheimer’s blood test diagnosis achieves diagnostic accuracy exceeding 90%, making it comparable to more invasive approaches such as PET brain imaging and lumbar puncture, also known as a spinal tap. According to NeuRA cognitive neurologist Dr. Emma Devenney, the technology represents “an opportunity to do a single blood test” with accuracy comparable to existing diagnostic tools.
The Therapeutic Goods Administration (TGA) has approved the pTau217 blood test for Alzheimer’s, while broader clinical rollout through physician referral pathways is expected over the coming months. Researchers also anticipate future integration into Australia’s healthcare system as additional validation studies continue.
Who Should Receive the Alzheimer’s Blood Test?
Despite its promise, experts emphasize that the Alzheimer’s blood test in Australia is not intended as a screening tool for healthy people. Instead, it is designed for individuals who are already experiencing memory loss, confusion, or other symptoms that may indicate cognitive decline.
Although the pTau217 biomarker can appear years before symptoms develop, a positive result does not predict exactly when, or even if, a person will develop Alzheimer’s disease. For this reason, researchers recommend using the test alongside a clinical assessment rather than as a standalone screening method.
New Centre to Accelerate Alzheimer’s Research Across the Region
The Alzheimer’s blood test in Australia coincides with the launch of the Asia-Pacific Centre of Excellence for Alzheimer’s Disease Diagnosis in Sydney, a collaboration between Neuroscience Research Australia (NeuRA) and Roche Diagnostics Australia.
The centre aims to improve early detection through advanced blood-based biomarker testing, support clinical trials, and strengthen dementia research across Australia and the wider Asia-Pacific region. Researchers also expect it to help standardize diagnostic pathways while expanding access to innovative technologies.
Researchers and patient advocates say earlier diagnosis offers benefits that extend beyond medical treatment. Dr. Emma Devenney said identifying Alzheimer’s earlier gives people more time to plan for the future while disease symptoms remain mild. She added that the blood test represents a significant step toward earlier treatment and, ultimately, better prevention strategies.
Why the Dementia Blood Test in Australia Matters?
Dementia is now Australia’s leading cause of death, with more than 446,500 Australians living with the condition. Alzheimer’s disease accounts for approximately 60–70% of dementia cases, placing growing pressure on patients, caregivers, and the healthcare system.
Diagnosing Alzheimer’s has traditionally been a slow and complicated process. Many patients experience months of uncertainty while waiting for specialist consultations, expensive PET scans, neuropsychological assessments, or lumbar punctures.
The Alzheimer’s blood test in Australia has the potential to simplify this pathway significantly. By making diagnosis faster, less invasive, and potentially more accessible, the technology could improve patient care while preparing Australia’s health system for future disease-modifying Alzheimer’s therapies. People living in rural and regional communities may eventually be able to access blood testing diagnosis through their general practitioner rather than traveling to major cities.
As clinical rollout progresses over the coming months, Australia’s First Alzheimer’s blood test will make significant change in dementia diagnosis and offer new hope for patients and families facing one of the world’s most challenging neurological diseases.
